Compare IVR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | TBPH |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.8M | 908.9M |
| IPO Year | 2008 | 2013 |
| Metric | IVR | TBPH |
|---|---|---|
| Price | $7.15 | $17.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.25 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 2.3M | 402.8K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | 103.08 | ★ 279.13 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $150.63 | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $71.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.10 | $13.08 |
| 52 Week High | $9.50 | $21.03 |
| Indicator | IVR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 62.07 |
| Support Level | N/A | $16.80 |
| Resistance Level | $7.63 | $17.11 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.03 | 75.68 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.